Literature DB >> 8237943

Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.

Y Takeuchi1, A Nakao, A Harada, T Nonami, T Fukatsu, H Takagi.   

Abstract

Expression of plasminogen activators (PA), tissue type (t-PA) and urokinase type (u-PA), as well as PA inhibitors (PAI), type-1 (PAI-1) and type 2 (PAI-2), were investigated immunohistochemically in 97 human pancreatic carcinomas. u-PA expression predominated in pancreatic carcinomas, compared with t-PA [u-PA expression in 76 specimens (78.4%) and t-PA in eight specimens (8.2%)]. PAI-1 expression was detected in 80 carcinoma specimens (82.5%) and PAI-2 in 79 carcinoma specimens (81.4%). PAI-2 expression was significantly lower in carcinomas with peritoneal metastasis (p < 0.02). Strong PAI-2 expression was associated with significantly higher survival than negative or weak PAI-2 expression (p < 0.05). We conclude that immunohistochemical analysis of PAI-2 expression in pancreatic carcinomas may yield important prognostic information.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8237943

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Analysis of the human pancreatic stellate cell secreted proteome.

Authors:  Angela Y Wehr; Emma E Furth; Vineet Sangar; Ian A Blair; Kenneth H Yu
Journal:  Pancreas       Date:  2011-05       Impact factor: 3.327

4.  Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.

Authors:  Benjamin L Barthel; Daniel L Rudnicki; Thomas Price Kirby; Sean M Colvin; David J Burkhart; Tad H Koch
Journal:  J Med Chem       Date:  2012-07-17       Impact factor: 7.446

5.  High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

Authors:  Ross Smith; AiQun Xue; Anthony Gill; Christopher Scarlett; Alexander Saxby; Adele Clarkson; Thomas Hugh
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

6.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

Review 7.  Role of proteases in pancreatic carcinoma.

Authors:  Lane C Patten; David H Berger
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

8.  A pilot study of urokinase-type plasminogen activator (uPA) overexpression in the brush cytology of patients with malignant pancreatic or biliary strictures.

Authors:  John F Gibbs; Michael Schlieman; Paramvir Singh; Rakhee Saxena; Maisie Martinick; Alan D Hutson; James Corasanti
Journal:  HPB Surg       Date:  2009-11-30

9.  Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.

Authors:  Chang F Qu; Emma Y Song; Yong Li; Syed M A Rizvi; Chand Raja; Ross Smith; Alfred Morgenstern; C Apostolidis; Barry J Allen
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

10.  Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer.

Authors:  Yu-Jing Huang; Marsha L Frazier; Nianxiang Zhang; Qian Liu; Chongjuan Wei
Journal:  Dig Dis Sci       Date:  2013-11-19       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.